Pinned post
Our paper is out in @Nature today! We resolved over 1.6 million cells from 416 lung cancer patients by imaging mass cytometry 😮! Buckle up…
Mark Sorin
@sorin_mark
@McGill_MDPhD | Vanier Scholar @CIHR_IRSC | Passionate about research in lung cancer & immunotherapy
1.1K Following 607 Followers 296 Posts
Latest posts 5
Our paper is out in Lancet Hematology!
thelancet.com/journals/lanha…
As both CAR-T and bispecific antibodies continue to move earlier in the treatment course for large-B cell lymphoma, the question of optimal treatment sequence of these two agents will become increasingly relevant.
thelancet.com/journals/lanha…
As both CAR-T and bispecific antibodies continue to move earlier in the treatment course for large-B cell lymphoma, the question of optimal treatment sequence of these two agents will become increasingly relevant.
www.thelancet.com Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lympho... Based on current evidence, our meta-analysis suggests that BsAb therapy before CAR-T could improve future CAR-T effectiveness for large B-cell lymphoma, although our conclusions are limited by small... Incredibly grateful to have received the CMHF Award! I am thankful for the unwavering support of my mentors, friends and family members who have made this possible. Excited for what is next!
2024 #CMHFAward recipient @sorin_mark from @McGillMed! He has made important contributions to the field of lung cancer. Inspired by Dr. Phil Gold for his transformative discovery for cancer care and his abundant generosity in mentoring students. cdnmedhall.ca/2024cmhfawardView quoted post on X
Our work was highlighted in a recent documentary!
Our paper is out today @JAMAOnc! We report a systematic review and meta-analysis of 43 studies related to neoadjuvant chemo-immunotherapy and chemotherapy involving 5431 patients with resectable NSCLC!
jamanetwork.com/journals/jamao…
jamanetwork.com/journals/jamao…
jamanetwork.com Neoadjuvant Chemoimmunotherapy for NSCLC This meta-analysis investigates the association of neoadjuvant chemoimmunotherapy with patient benefits vs neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC).